Propeller Health researchers to present new findings at ATS 2021

The American Thoracic Society (ATS) 2021 International Conference begins today and we’re looking forward to another event bringing together the world’s leading respiratory experts. The Propeller and ResMed teams will be presenting a number of abstracts and look forward to rich discussions.

Mini Symposium 

Leanne Kaye, PhD, MPH, Senior Behavior Scientist at ResMed, will lead a presentation and live Q&A session on an analysis exploring temporal patterns of controller medication use among 3,455 Propeller users with asthma and COPD. 

Title: Controller Use Timing Among Participants Using Once-Daily Controller Medications in Asthma and COPD

Session: C008 Innovations and Updates in the Study and Management of COPD 

Date/Time: Tuesday, May 18, 2021 at 10:00 a.m. ET / 7:00 a.m. PT

Posters

The Propeller and ResMed Research teams also contributed four posters to this year’s event.

1. Title: Predicting Peak and Cumulative Ventilator Need for COVID-19 in the US: Development of an Epidemiological Model

Session: TP050 COVID: Nonpulmonary Critical Care, Mechanical Ventilation, Behavioral Sciences, and EPI 

Summary: A new predictive model may inform resource planning and allocation for which patients require ventilators in subsequent waves of COVID-19.

2. Title: Predicting Daily Short-Acting Beta-Agonist (SABA) Inhaler Actuations Using a Time-Convolutional Neural Network

Session: TP015 Updates in Adherence and Treatment of Lung Disease 

Summary: Propeller developed a model using a time-convolutional neural network to predict future worsening of asthma based on rescue inhaler usage data.

3. Title: Improvement in Inhaled Short-acting Beta-agonist (SABA) Use by Education and Income Among Adults Enrolled in a Digital Asthma Program

Session: TP015 Updates in Adherence and Treatment of Lung Disease 

Summary: Propeller users experience similar reductions in rescue inhaler use, irrespective of income and education level.

4. Title: An Estimate of the Americas’ Prevalence of Chronic Obstructive Pulmonary Disease in 2050

Session: TP41 COPD, Emphysema, Chronic Bronchitis, Alpha-1 Antitrypsin Deficiency

Summary: This analysis projected a substantial increase in COPD prevalence based on age and population growth. Such an increase could have significant health and economic impact.

Hopefully, by next year’s event, we’ll be able to see you all in person. Until then, we look forward to connecting with you virtually at the conference! 

Questions about Propeller’s peer-reviewed clinical research? Email help@propellerhealth.com.